(A) two inhibitor-positive haemophilia patients (1 and 2), (B) four inhibitor-negative haemophilia patients (4-7) and (C) patient 4 either at baseline, at loading phase (LP) or at maintenance phase (MP) of emi treatment are shown. We acknowledge our patients for their participation to this study. Three inhibitor-positive (titre >0.6 BU/ml) haemophilia patients (patients 1-3) were treated with emi and followed for several months as part of the STASEY trial protocol. The emi regimens were as follows: 1) inhibitor-positive patients: loading doses at 180-258 mg (median 230 mg; 3 mg/kg in all) and standard doses at 90-120 mg (median 123 mg; 1.5 mg/kg in all), and 2) non-inhibitor patients: loading doses at 210-270 mg (median 232.5 mg; 3 mg/kg in three patients and 2.5 mg/kg in patient 4), and the standard doses at 105 mg (1.0- 1.3 mg/kg). [Extracted from the article]